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Background: The evaluation, counseling, and management of gynecologic patients with bone metastasis remain a
challenge for clinicians. In order to critically evaluate the role of surgery, we retrospectively analyzed the records of
18 patients surgically treated for metastatic gynecologic tumors of bone, focusing on quality of life, local tumor
control, and survival.
Methods: Eighteen patients underwent surgical procedures for the treatment of bone metastases secondary to
gynecologic cancer between September 2003 and April 2012. The primary cancer sites included the uterus (n = 10),
the cervix (n = 5), and an ovary (n = 3). Patients were followed for an average period of 13.8 months (range, 2 to
34 months). A visual analog pain scale (VAS) and Eastern Cooperative Oncology Group (ECOG) performance status
were evaluated both pre- and postoperatively.
Results: The median survival time following diagnosis of bone metastasis was 10.0 months. The mean VAS score
was 5.8 preoperatively compared with 2.1, 3 months after surgery. The mean pre and postoperative ECOG
performance status grades were 3.1 and 2.3, respectively.
Conclusions: The prognosis of gynecological cancer patients with bone metastasis is poor. Some patients had
improvement in their quality of life after surgical intervention for bone metastases; however, novel integrated
treatment modalities should be investigated.
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Ovarian, uterine and cervical cancer will affect an esti-
mated 80,000 women in the United States, with 27,000
deaths [1]. Improvements in surgery, radiation and the
development of novel chemotherapeutic agents have led
to prolonged survival and an increase in the prevalence
of bone metastasis [2]. The incidence of bone metastasis
secondary to endometrial cancer is reported to be 6 to
15% [3,4]. Bone metastases occur in approximately 1.2%
of patients with ovarian cancer [5] and represent the
third most common site of metastasis in cervical cancer, oc-
curring in 1.1% of patients [6,7]. Traditionally, radiotherapy* Correspondence: bonetumor@163.com
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reproduction in any medium, provided the oris considered the first line treatment in the management
of metastatic bone lesions [8].
Traditionally, patients with bone metastasis have
advanced stage disease, and the utility of surgical inter-
vention is unclear. Some advocate minimal intervention
and aggressive pain control, while others support more
aggressive surgical intervention due to the unresponsive-
ness of these metastatic lesions to chemotherapy, radio-
therapy and other noninvasive measures. The established
indications for surgery include impending or existing
pathological fractures, spinal cord compression, and pain,
especially for patients who became resistant to radiothe-
rapy [9,10].
The evaluation, counseling, and management of gyneco-
logic cancer patients with bone metastasis remain a chal-
lenge for practicing gynecologic oncologists. Existing
reports on surgical treatment and outcomes are of limitedhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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follow-up data [11-14]. In order to critically analyze the
role of surgery in this patient population, we retrospect-
ively analyzed the records of 18 patients surgically treated
for metastatic gynecologic tumors of bone, focusing on
quality of life, functional outcome, local tumor control,
and survival.
Methods
Following institutional review board approval, we con-
ducted a retrospective review of patients undergoing
surgical procedures for metastatic gynecologic tumors
over a nine-year period (September 2003 to April 2012).
The study is approved by the Ethical and Professional
Committee of People’s Hospital. Informed consent was
obtained from all the patients. Patients were identified
from the institutional cancer registry and cross-referenced
to the pathology database.
The median age at diagnosis was 55.0 years (range, 35
to 76 years). Primary tumor identification was based on
pathologic diagnosis and correlated, when appropriate, to
initial surgical specimens. Patients were followed for an
average period of 13.8 months (range, 2 to 34 months).
Patient information is summarized in Table 1. The
primary cancer sites were uterus (n = 10; two with leio-
myosarcoma), cervix (n = 5), and ovary (n = 3). Twelve
of the 18 patients who were referred initially received
gynecological treatment somewhere else. Bone was the
only site of identifiable metastasis in 15 patients. The
mean interval from the primary diagnosis of gynecologic
cancer to the detection of bone metastasis was 21.8 months
(range, 0 to 48 months). Two patients were referred with
acute partial paralysis before the primary tumor was iden-
tified. Patients included in this review were referred to our
institution from various hospitals, and thus, up-front
treatment for their primary gynecologic malignancy was
not uniform.
Indications for orthopedic surgery [15] included in-
tractable pain in ten patients (56%), impending or patho-
logical fracture in five (28%) patients, and spinal cord
compression in three patients (16%). Wide resection
consisting of en bloc removal of the bone lesion with an
envelope of normal tissue and reconstruction was done
in five patients. Intra-lesional curettage followed by in-
ternal fixation was performed in 13 patients (Figure 1).
Palliative decompression for spinal cord compression
was performed in four patients. All the patients received
bisphosphonate treatment monthly after surgery.
The primary functional outcome was defined as im-
provement in the specific pain and performance status
for which the surgical intervention was performed. Pa-
tients were evaluated preoperatively and every three
months after surgery. A visual analog pain scale (VAS)
was used to evaluate the degree of pain both before andafter surgery. An Eastern Cooperative Oncology Group
(ECOG) performance status was evaluated both pre- and
post-operatively. This measured functional performance
on a scale from 0 to 4, where 0 represents normal activity
and 4 signifies complete bed rest. In order to minimize
the impact of cancer recurrence on the primary outcome
of pain improvement and performance status, we focused
the analysis on immediate pre-operative assessment and
that occurring in the initial 3 months after surgical
intervention.
Statistical analysis was performed using Statistical
Package for the Social Science (SPSS) software version
20.0 (SPSS Inc, USA). A comparison of parametric out-
come data was performed with a paired t test. A Kaplan-
Meier survival method was used to estimate patient
survival.
Results
At completion of data collection, 15 patients were dead
of primary disease, and 2 patients were alive without evi-
dence of disease recurrence. One patient (patient 16) de-
veloped pulmonary metastasis 19 months after femur
surgery and is alive with disease. New bone lesions oc-
curred in two patients (patient 5 and 8) during the
follow-up and no simultaneous surgical intervention was
performed. The survival curve for the 18 patients is
shown in Figure 2. The median survival time following
diagnosis of bone metastasis was 10.0 months (95% CI,
3.8 go 16.2 months). The estimated 1-year survival was
44.4%. The eight patients with endometrial carcinoma
had a median survival of 10.0 months (95% CI 0 to
22.5 months), patients with cervical cancer 6.0 months
(95% CI 4.9 to 7.1 months), and ovarian carcinoma
8.0 months (95% CI 4.8 to 11.2 months).
The mean VAS pain scale score was 5.8 (SD 1.5) pre-
operatively compared with 2.1 (SD 1.9) 3 months after
surgery. There was a significant improvement in pain
3 months after surgical intervention (P <0.001). Pain re-
lief was observed in 17 patients (94.4%). The mean pre-
and post-operative ECOG performance status grades for
all 18 patients were 3.1 (SD 0.9) and 2.3 (SD 1.1), respect-
ively. Post-operatively, five patients (27.8%) performed
well (ECOG performance status of 1 or 0) compared with
only one (5.6%) pre-operatively. The paired samples t-test
showed a statistically significant improvement in ECOG
performance status (P = 0.02). Improvement in perform-
ance status was seen in 12 of the 18 patients (66.7%). The
performance of two patients remained unchanged and
four (22.2%) deteriorated.
There were a total of 6 complications among the 18
patients, for an overall complication rate of 33.3%. Two
lesions (patient 6 and 12) recurred following curettage,
neither of these patients received additional radiother-
apy. Two patients developed an infection or wound


































1 59 EC IVA Chemo + RT 37 Sacrum IP RT 6/1 3/1 10 DOD
2 68 EC IIIB Surg + Chemo 9 Pubic bone IP CT 4/0 2/1 30 DOD
3 48 OC IIIC Chemo 22 Humerus PF 5/1 2/1 8 DOD
4 75 OC IVB Chemo + RT at diagnosis Spine/T3 PF + SCC 4/1 4/2 6 DOD
5 51 EC IVB Surg + Chemo 19 Spine/T5 Lung SCC 6/2 3/3 13 DOD
6 63 OC IIIB RT 8 Spine/L2,3 IP 8/4 4/3 11 DOD
7 55 CC IIB Surg + Chemo 16 Femur PF RT 4/3 4/2 15 DOD
8 55 EC IIIC Surg + Chemo + RT 26 Spine/L3 IP 4/1 3/2 28 DOD
9 45 EC IVB Chemo + RT at diagnosis Spine/T12 Liver SCC 7/2 3/4 3 DOD
10 55 EC IVA Surg + Chemo 16 Spine/L3 Liver IP 6/8 4/2 16 DOD
11 55 EC❖ IIA Surg + Chemo 39 Femur IP CT 6/1 3/1 34 NED
12 58 EC II Surg + Chemo 48 Acetabulum*/L1 IP 8/3 4/4 4 DOD
13 46 CC IIB Surg + Chemo + RT 25 Pubic bone IP 7/3 1/2 6 DOD
14 35 CC IIIB Chemo + RT 14 Sacrum*/
Ilium
IP RT 9/1 4/2 6 DOD
15 76 EC IIIB Surg + Chemo + RT 10 Spine/L3 Lung IP RT 6/4 3/4 4 DOD
16 56 EC❖ IB Surg + Chemo 12 Femur PF 4/1 4/2 24 AWD
17 46 CC IIIB Chemo + RT 20 Femur PF CT 5/0 3/1 20 NED
18 47 CC IIB Surg + Chemo + RT 27 Humerus*/
Ilium
PF RT 6/1 2/4 5 DOD
AWD, alive with disease; CC, cervical cancer; Chemo, chemotherapy; DOD, died of disease; EC, endometrial carcinoma; EC❖, uterine leiomyosarcoma; IP, intractable pain; NED, no evidence of disease; OC, ovarian
carcinoma; PF, pathological fractures; RT, radiotherapy; SCC, spinal cord compression; Surg, surgery.


















Figure 1 The patient was diagnosed for cervical cancer (Number 14). X-ray (A) and computed tomography (CT) (B) showed a large sclerotic
lesion involving the sacrum. Intraoperative picture (C) demonstrated sacral nerve roots preserved after resection of metastatic lesion. Pathological
examination revealed squamous cell carcinoma (D) (hematoxylin and eosin (H&E) stain, ×100). Postoperative x-ray (E) showed screw-rod system
reconstruction.
Figure 2 The Kaplan-Meier survival curve showed patients’ survival after bone metastases from gynecological malignancies.
The median survival time from diagnosis of bone metastasis was 10.0 months (95% confidence interval (CI), 3.8 to 16.2 months).
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Figure 3 Representative case showed pathological fracture in
femoral neck of patient number 17. The preoperative X ray
showed the pathological fracture (A).A proximal femoral endoprosthesis
was used to reconstruct the bone defect (B). Histological appearance
(C) of the lesion featuring infiltration by poorly differentiated
squamous carcinoma cells (hematoxylin and eosin (H&E) stain, ×200).
Immunohistochemically, the tumor was positive for 34βE12 +, CK5/6 +
and p63 +.
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fluid leak was diagnosed in patient 8, and was managed
conservatively. Femoral vein thrombosis occurred in one
patient.
Discussion
Recurrent gynecologic cancers are not confined to the
abdominal peritoneal cavity. These diseases exhibit a sig-
nificant potential for distant metastases, even at early
stages, as evidenced by the identification of bone metas-
tases in cervical cancer patients with suspected clinical
stage 2B disease. In a study of hematogenous metastases
in patients with FIGO Stage 1 or 2 endometrial carci-
noma, 134 metastatic sites were identified in a total of
110 patients, and bone involvement was observed in 23
patients [16].
Chang et al. [17] described a case of FIGO stage IA
epithelial ovarian cancer with bone as the first site of re-
current disease. The treatment of patients with bone
metastases should be tailored to the individual patient
and based on factors such as age, performance status,
presence of simultaneous metastasis, and site of bone
affected. The primary goal of surgical intervention is to
eliminate or alleviate pain and preserve quality of life,
with a possible prolongation of life [18]. There are few
previous reports detailing both quality of life parameters
and functional outcomes following surgical treatment
for recurrent gynecological malignancies presenting as
bone metastasis.
Two mechanisms for osseous metastasis in gyneco-
logic cancer have been described [19]. Direct invasion
into bone from loco-regional or distant soft tissue tumor
masses is one mechanism, and hematogenous spread
through the systemic circulation or the Batson venous
plexus is another. In the current series, 66.7% of meta-
static lesions were in the pelvic girdle or spine. The
spread to lower limb bones is thought to occur primarily
via venous retrograde flow of tumor emboli [20,21].
In a study of 377 patients, 25% of patients with loco-
regionally restricted gynecologic cancer were found to
have disseminated tumor cells in bone marrow at diag-
nosis. Loizzi et al. [22] reviewed 21 endometrial cancer
patients with bone metastasis from 20 published reports.
They found the median interval between the detection
of endometrial cancer and bone metastasis to be
21 months, similar to the mean interval of 21.8 months
identified in the current study. An analysis on bone me-
tastasis in cervical cancer patients over a 10-year period
showed the median duration from diagnosis of cervical
cancer to bone metastasis was 16 months and the me-
dian survival was 7 months following intervention for
this subgroup of patients [6]. In a retrospective review of
103 ovarian cancer cases, four patients had bone in-
volvement with a median survival of 7.5 months [23].These survival results mirror our experience, with median
survival of 10 months for endometrial cancer, 8 months
for ovarian cancer, and 6 months for cervical cancer.
Estimating survival in patients with bone metastases is
imperative in surgical treatment planning [8,24,25]. How-
ever, there are challenges inherent to predicting survival
[10]. Three-month and 12-month time points were con-
sidered to be useful discriminators for surgical decision-
making. It is well accepted that survival less than 3 months
is a relative contraindication to surgical intervention, with
specific exceptions such as acute spinal cord compression.
Shorter life expectancies (3 to 12 months) are thought to
warrant less invasive stabilization procedures, while longer
life expectancies (>12 months) warrant more durable
reconstruction, which is usually associated with operative
morbidity and a longer period of convalescence [26].
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implants have been used to achieve more durable recon-
structions in metastatic conditions [27].
The ECOG performance status was found to be a sig-
nificant prognostic factor in prior studies investigating
management of metastatic bone disease. The simplicity
of use and reproducibility make it a valuable index for
prognostication [10,28]. A statistical study based on
Bayesian methods identified ECOG performance status
and presence of visceral metastases as the most impor-
tant in developing surgeon’s estimate of survival [26].
The prognosis of bone metastases from breast cancer or
prostate cancer is measurable in years. In contrast, the
median survival time form the diagnosis of advanced
lung cancer is typically measured in months [29,30]. Due
to the rarity of bone metastasis from gynecologic malig-
nancies, the prognosis of these patients after surgical
treatment has not been well established.
The oncological objective of excising metastatic tumor
of bone is the achievement of local tumor control. How-
ever, skeletal-related events involving pathological frac-
tures, spinal cord compression and a need for surgery
and/or radiotherapy may potentially have detrimental ef-
fects on survival and quality of life. In this study, surgical
intervention for the treatment of bone metastases
resulted in a significant improvement in pain as well as
ECOG performance status. When a cure is not achie-
vable, palliation of symptoms and improvements in
quality of life should be a priority.
Intralesional curettage can decrease rates of local re-
currence, avoiding the need for extensive resection and
reconstruction. More aggressive local and systemic treat-
ment is advocated for improved local control [28]. Add-
itionally, current systemic treatments and improvements
in supportive care have translated into prolonged sur-
vival following management of bone metastases. These
factors have compelled more aggressive operative proce-
dures, although indications remain controversial. En bloc
resection may be more appropriate when advanced dis-
ease precludes internal fixation, or when the metastatic
disease is limited to a solitary bony deposit. Five patients
received en bloc resection in the current study, three of
which were for proximal femoral lesions (Figure 3). Out-
comes of internal fixation for this site are often unfavor-
able, with high nonunion rate (65%), high local recurrence
rate (48%), and high implant failure rate (23%) [31-33].
Use of endoprostheses demonstrates a lower mechanical
failure rate and a higher rate of implant survivorship [31].
It is acknowledged that there are limitations to this
study. The present series is a retrospective review and
therefore susceptible to the same limitations and biases
inherent to all retrospective studies. There is no control
group and it is unlikely that ethical approval would be
given for a no-treatment or no-surgical interventiongroup. Nonetheless, this paper is among the largest
series published to date on surgical treatment for bone
metastases in gynecological tumors and is the first to
document quality of life and functional parameters after
treatment.
Conclusions
In conclusion, the management and counseling of patients
with gynecologic cancers metastatic to bone is difficult.
Specifically, prognosis of gynecological cancer patients
with bone metastasis is poor. Nonetheless, following sur-
gical intervention, improvements in quality of life have
been described. Given the small number of patients and
heterogeneity of our study population, no definite conclu-
sions can be drawn. A prospective, multi-institutional
study may allow for collection of more comprehensive
data, helping guide gynecologic oncologists in the coun-
seling of such patients.
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